|
1) 持田 智, 中山伸朗, 森吉美穂, 他. ㈰ 劇症肝炎の診断基準: プロトロンビン時間の扱いに関する検討, ㈪ 劇症肝炎, 急性肝不全の概念の改変, ㈫ 肝移植適応ガイドラインの改訂. 厚生労働省科学研究費補助金(難治性疾患克服研究事業)｢難治性の肝・胆道疾患に関する調査研究班｣平成19年度報告書. 2008. p. 110-3
|
|
|
|
|
2) 坪内博仁, 桶谷 真, 井戸章雄, 他. 劇症肝炎, 遅発性肝不全(LOHF: late onset hepatic failure)の全国調査(2006年). 厚生労働省科学研究費補助金(難治性疾患克服研究事業)｢難治性の肝・胆道疾患に関する調査研究班｣平成19年度報告書. 2008. p. 83-94
|
|
|
|
|
|
3) 森 満, 板内 文, 鷲尾昌一, 他. 全国疫学調査による難治性の肝疾患の日本の患者数の推計. 厚生労働省科学研究費補助金｢特定疾患の疫学に関する研究班｣平成17年度報告書. 2006. p. 39-42
|
|
|
|
|
|
4) Fujiwara K, Mochida S, Matsui A, et al. Intractable Liver Diseases Study Group of Japan. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res. 2008; 38: 646-57
|
|
|
|
|
5) Sainokami S, Abe K, Sato A, et al. Initial load of hepatitis B virus (HBV), its changing profile, and precore/core promoter mutations correlate with the severity and outcome of acute HBV infection. J Gastroenterol. 2007; 42: 241-9
|
|
|
|
|
6) Hayashi K, Katano Y, Takeda Y, et al. Association of hepatitis B virus subgenotypes and basal core promoter/precore region variants with the clinical features of patients with acute hepatitis. J Gastroenterol. 2008; 43: 558-64
|
|
|
|
|
|
7) Jammeh S, Tavner F, Watson R, et al. Effect of basal core promoter and pre-core mutations on hepatitis B virus replication. J Gen Virol. 2008; 89: 901-9
|
|
|
|
|
|
8) Sugiyama M, Tanaka Y, Kurbanov F, et al. Influences on hepatitis B virus replication by a naturally occurring mutation in the core gene. Virology. 2007; 365: 285-91
|
|
|
|
|
|
9) Ozasa A, Tanaka Y, Orito E, et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology. 2006; 44: 326-34
|
|
|
|
|
|
10) Sugauchi F, Orito E, Ohno T, et al. Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. Hepatol Res. 2006; 36: 107-14
|
|
|
|
|
|
11) 坪内博仁, 桶谷 真. 劇症肝炎, 遅発性肝不全(LOHF: late onset hepatic failure)の全国調査(2004年). 厚生労働省科学研究費補助金(難治性疾患克服研究事業)｢難治性の肝・胆道疾患に関する調査研究班｣平成17年度報告書. 2006. p. 61-9
|
|
|
|
|
|
12) 坪内博仁, 桶谷 真. 劇症肝炎, 遅発性肝不全(LOHF: late onset hepatic failure)の全国調査(2005年). 厚生労働省科学研究費補助金(難治性疾患克服研究事業)｢難治性の肝・胆道疾患に関する調査研究班｣平成18年度報告書. 2007. p. 90-100
|
|
|
|
|
|
13) Umemura T, Kiyosawa K. Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Intern Med. 2006; 45: 747-8
|
|
|
|
|
|
14) Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006; 131: 59-68
|
|
|
|
|
|
15) 坪内博仁. 劇症肝炎に関する研究. 厚生労働省科学研究費補助金(難治性疾患克服研究事業)｢難治性の肝・胆道疾患に関する調査研究班｣平成19年度報告書. 2008. p. 10-1
|
|
|
|
|
|
16) Torisu T, Nakaya M, Watanabe S, et al. Suppressor of cytokine signaling 1 protects mice against concanavalin A-induced hepatitis by inhibiting apoptosis. Hepatology. 2008; 47: 1644-54
|
|
|
|
|
|
17) Numata K, Kubo M, Watanabe H, et al. Overexpression of suppressor of cytokine signaling-3 in T cells exacerbates acetaminophen-induced hepatotoxicity. J Immunol. 2007; 178: 3777-85
|
|
|
|
|
|
18) Lu JW, Wang H, Yan-Li J, et al. Differential effects of pyrrolidine dithiocarbamate on TNF-α-mediated liver injury in two different models of fulminant hepatitis. J Hepatol. 2008; 48: 442-52
|
|
|
|
|
|
19) Tanaka H, Uchida Y, Kaibori M, et al. Na＋/H＋ exchanger inhibitor, FR183998, has protective effect in lethal acute liver failure and prevents iNOS induction in rats. J Hepatol. 2008; 48: 289-99
|
|
|
|
|
|
20) Goto T, Takeuchi S, Miura K, et al. Suramin prevents fulminant hepatic failure resulting in reduction of lethality through the suppression of NF-κΒactivity. Cytokine. 2006; 33: 28-35
|
|
|
|
|
|
21) Hijikawa T, Kaibori M, Uchida Y et al. Insulin-like growth factor 1 prevents liver injury through the inhibition of TNF-α and iNOS induction in D-galactosamine and LPS-treated rats. Shock. 2008; 29: 740-7
|
|
|
|
|
|
22) Eipel C, Kidess E, Abshagen K, et al. Antileukoproteinase protects against hepatic inflammation, but not apoptosis in the response of D-galactosamine-sensitized mice to lipopolysaccharide. Br J Pharmacol. 2007; 151: 406-13
|
|
|
|
|
|
23) Odashima M, Otaka M, Jin M, et al. A selective adenosine A2A receptor agonist, ATL-146e, prevents concanavalin A-induced acute liver injury in mice. Biochem Biophys Res Commun. 2006; 8; 347: 949-54
|
|
|
|
|
|
24) Fukuda T, Mogami A, Tanaka H, et al. Y-40138, a multiple cytokine production modulator, protects against D-galactosamine and lipopolysaccharide-induced hepatitis. Life Sci. 2006; 79: 822-7
|
|
|
|
|
|
25) Cuesta E, Boada J, Calafell R, et al. Fructose 1, 6-bisphosphate prevented endotoxemia, macrophage activation, and liver injury induced by D-galactosamine in rats. Crit Care Med. 2006; 34: 807-14
|
|
|
|
|
|
26) Tsui TY, Obed A, Siu YT, et al. Carbon monoxide inhalation rescues mice from fulminant hepatitis through improving hepatic energy metabolism. Shock. 2007; 27: 165-71
|
|
|
|
|
|
27) Wright G, Shawcross D, Olde Damink SW, et al. Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension. Metab Brain Dis. 2007; 22: 375-88
|
|
|
|
|
|
28) Stadlbauer V, Krisper P, Aigner R, et al. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care. 2006; 10: R169
|
|
|
|
|
|
29) Ilonen I, Koivusalo AM, Hockerstedt K, et al. Albumin dialysis has no clear effect on cytokine levels in patients with life-threatening liver insufficiency. Transplant Proc. 2006; 38: 3540-3
|
|
|
|
|
|
30) Van Laecke S, De Wilde K, Vanholder R. Online hemodiafiltration. Artif Organs. 2006; 30: 579-85
|
|
|
|
|
|
31) Canaud B, Chenine L, Henriet D, et al. Online hemodiafiltration: a multipurpose therapy for improving quality of renal replacement therapy. Contrib Nephrol. 2008; 161: 191-8
|
|
|
|
|
|
32) 荒田慎寿, 高山和久, 南 和敏, 他. On line HDFを用いた人工肝補助療法の確立と今後の課題. 肝臓. 2008; 49: A50
|
|
|
|
|
|
33) 井上和明, 山田雅哉, 渡邊綱正, 他. 急性肝不全治療ガイドラインにおける人工肝補助は如何にあるべきか. 第34回日本急性肝不全研究会プログラム及び抄録集. 2008. p. 28
|
|
|
|
|
|
34) Belanger M, Desjardins P, Chatauret N, et al. Mild hypothermia prevents brain edema and attenuates up-regulation of the astrocytic benzodiazepine receptor in experimental acute liver failure. J Hepatol. 2005; 42: 694-9
|
|
|
|
|
|
35) Stravitz RT, Lee WM, Kramer AH, et al. Therapeutic hypothermia for acute liver failure: toward a randomized, controlled trial in patients with advanced hepatic encephalopathy. Neurocrit Care. 2008; 9: 90-6
|
|
|
|
|
|
36) 坪内博仁, 井戸章雄, 沼田政嗣, 他. 劇症肝炎に対する組換型ヒト肝細胞増殖因子(fh-HGF)の第I/II｢相臨床試験. 厚生労働省科学研究費補助金(難治性疾患克服研究事業)｢難治性の肝・胆道疾患に関する調査研究班｣平成19年度報告書. 2008. p. 95-6
|
|
|
|
|
|
37) Terai S, Ishikawa T, Omori K, et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cell. 2006; 24: 2292-8
|
|
|
|
|
|
38) Mochida S, Nakayama N, Matsui A, et al. Re-evaluation of the Guideline published by the Acute Liver Failure Study Group of Japan in 1996 to determine the indications of liver transplantation in patients with fulminant hepatitis. Hepatol Res. 2008. in press
|
|
|
|
|